Ladenburg starts Marinus Pharma at buy; PT $20

Marinus Pharma

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5.

Marinus is developing ganaxolone (GNX), a synthetic analog of the neuroactive steroid, allopregnanolone, to treat patients with CDKL5 deficiency disorder, an ultra-rare condition without effective therapies for which GNX has significantly and durably reduced seizure frequency. GNX is on track for a late 2020 approval, writes analyst Michael Higgins.

He said Marinus also is pursuing a much larger opportunity with its IV/oral GNX in postpartum depression (PPD), with Phase 2 data in the second half of 2018, which is about two years behind Sage Therapeutics and its IV allopregnanolone, brexanolone.

“We expect Marinus shares may rally through year-end, as comparisons to Sage pick up,” he said.

In the second half of 2018, he expects to see the first Phase 2 results from Marinus’ GNX in PPD. “First in the third quarter, IV-to-oral GNX in severe PPD, the “Magnolia” trial. Then in the fourth quarter, oral GNX in moderate PPD, the “Amaryllis” trial,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.